With research increasingly confirming that chemotherapy encourages the spread of cancer, a new article funded by a pharmaceutical company and published in The American Journal of Managed Care has claimed that reports of the demise of the toxic cancer treatment are ‘greatly exaggerated’.
The medical journal article described here was funded by Athenex, a pharmaceutical company that specializes in developing drugs for cancer. Athenex also provided editorial review for the article. Significantly, therefore, two of the five article’s authors have, or have had, employment and stock ownership links to Athenex. A third author has, or has had, employment and stock ownership with Cardinal Health, a multinational health care services company that conducted the literature review and drafted the manuscript content for the article. Such conflicts of interest are of course common in medical journal articles and studies promoting the interests of the drug industry.
In reality, of course, research clearly confirms that chemotherapy encourages the spread of cancer. A recent study published in the Nature Cell Biology journal looked at two commonly used chemotherapy drugs, paclitaxel and doxorubicin, and examined how breast cancer cells respond to them. Confirming what other studies have reported for years now, the researchers found that use of this extremely toxic class of drugs can trigger the onset of new tumors in other parts of the body.
To learn more about how chemotherapy encourages the spread of cancer, read this article on our website.
To learn about the Cellular Medicine breakthrough which proves that specific micronutrients can inhibit the spread and invasion of cancer cells, read the book ‘Victory Over Cancer’, authored by Dr. Rath with Dr. Aleksandra Niedzwiecki.